Joshua D.I. Ellenhorn, M.D., FACS

Joshua D.I. Ellenhorn, M.D., FACS

Dr. Ellenhorn is a board-certified surgeon currently affiliated with Cedars-Sinai Marina del Rey Hospital. He earned his medical degree from Boston University School of Medicine, completing his residency program at the University of Cincinnati Hospital. He performed research fellowship training at the University of Chicago in Immunology and completed his Surgical Oncology fellowship at the Memorial Sloan-Kettering Cancer Center in New York. Dr. Ellenhorn is a leading expert in minimally invasive General Surgery and Surgical Oncology, with a clinical focus on innovative treatments of different types of cancer. Dr. Ellenhorn has been recognized for his expertise in surgery, and he is a member of the surgical oncology community. He is also an active member and fellow of several surgical societies.

Procedures Dr. Joshua Ellenhorn Performs at Cedars-Sinai Marina del Rey Hospital

Insurance Accepted

  • Blue Cross of California
  • Blue Shield of California
  • Cigna
  • HealthNet
  • Molina Healthcare

Languages Spoken

  • English

Education & Training

Medical Degree

Boston University School of Medicine


University Hospital - University of Cincinnati College of Medicine


University Hospital - University of Cincinnati College of Medicine


University of Chicago

Memorial Sloan-Kettering Cancer Center

Honors & Awards

Memberships & Affiliations

  • Society of Surgical Oncology Society of Surgical Oncology
  • Los Angeles Surgical Society Los Angeles Surgical Society
  • American College of Surgeons American College of Surgeons
  • American Society of Clinical Oncology American Society of Clinical Oncology
  • Publications & Media

    • The impact of lymph node number on survival in patients with lymph node-negative pancreatic cancer.

      Hellan, M., Sun, C. L., Artinyan, A., Mojica-Manosa, P., Bhatia, S., Ellenhorn, J. D., Kim, J.

    • Metastatic gastrointestinal stromal tumors in the era of imatinib: improved survival and elimination of socioeconomic survival disparities.

      Artinyan, A., Kim, J., Soriano, P., Chow, W., Bhatia, S., Ellenhorn, J. D.

    • Adjuvant radiation therapy is associated with improved survival in Merkel cell carcinoma of the skin.

      Mojica, P., Smith, D., Ellenhorn, J. D.

    • The anatomic location of pancreatic cancer is a prognostic factor for survival.

      Artinyan, A., Soriano, P. A., Prendergast, C., Low, T., Ellenhorn, J. D., Kim, J.

    • Totally laparoscopic gastric resection with extended lymphadenectomy for gastric adenocarcinoma.

      Guzman, E. A., Pigazzi, A., Lee, B., Soriano, P. A., Nelson, R. A., Benjamin Paz, I., Trisal, V., Kim, J., Ellenhorn, J. D.

    • Race and ethnicity correlate with survival in patients with gastric adenocarcinoma.

      Kim, J., Sun, C. L., Mailey, B., Prendergast, C., Artinyan, A., Bhatia, S., Pigazzi, A., Ellenhorn, J. D.

    • CC chemokine receptor 9 enhances proliferation in pancreatic intraepithelial neoplasia and pancreatic cancer cells.

      Shen, X., Mailey, B., Ellenhorn, J. D., Chu, P. G., Lowy, A. M., Kim, J.

    • The incidence and outcomes of pancreatectomy in patients with metastatic pancreatic adenocarcinoma.

      McKenzie, S., Mailey, B., Artinyan, A., Kim, J., Ellenhorn, J. D.

    • Pancreatic adenocarcinoma.

      Tempero, M. A., Arnoletti, J. P., Behrman, S., Ben-Josef, E., Benson, A. B., Berlin, J. D., Cameron, J. L., Casper, E. S., Cohen, S. J., Duff, M., Ellenhorn, J. D., Hawkins, W. G., Hoffman, J. P., Kuvshinoff, B. W., Malafa, M. P., Muscarella, P., Nakakura, E. K., Sasson, A. R., Thayer, S. P., Tyler, D. S., Warren, R. S., Whiting, S., Willett, C., Wolff, R. A.

    • Minimally invasive total gastrectomy for gastric cancer: a pilot series.

      Kachikwu, E. L., Trisal, V., Kim, J., Pigazzi, A., Ellenhorn, J. D.

    • Modified vaccinia Ankara expressing survivin combined with gemcitabine generates specific antitumor effects in a murine pancreatic carcinoma model.

      Ishizaki, H., Manuel, E. R., Song, G. Y., Srivastava, T., Sun, S., Diamond, D. J., Ellenhorn, J. D.

    • Heterologous prime/boost immunization with p53-based vaccines combined with toll-like receptor stimulation enhances tumor regression.

      Ishizaki, H., Song, G. Y., Srivastava, T., Carroll, K. D., Shahabi, V., Manuel, E. R., Diamond, D. J., Ellenhorn, J. D.

    • Neoadjuvant therapy is associated with improved survival in resectable pancreatic adenocarcinoma.

      Artinyan, A., Anaya, D. A., McKenzie, S., Ellenhorn, J. D., Kim, J.

    • Enhancement of cancer vaccine therapy by systemic delivery of a tumor-targeting Salmonella-based STAT3 shRNA suppresses the growth of established melanoma tumors.

      Manuel, E. R., Blache, C. A., Paquette, R., Kaltcheva, T. I., Ishizaki, H., Ellenhorn, J. D., Hensel, M., Metelitsa, L., Diamond, D. J.

    • Recombinant modified vaccinia virus ankara (MVA) expressing wild-type human p53 induces specific antitumor CTL expansion.

      Song, G. Y., Srivastava, T., Ishizaki, H., Lacey, S. F., Diamond, D. J., Ellenhorn, J. D.

    • Selection criteria for complete cytoreduction after cytoreductive surgery for peritoneal surface malignancy: lessons learned from our first series of patients.

      McKenzie, S., Artinyan, A., Holt, A. D., Garcia-Aguilar, J., Ellenhorn, J., Morgan, R., Paz, B.

    • Disparities in reconstruction rates after mastectomy: patterns of care and factors associated with the use of breast reconstruction in Southern California.

      Kruper, L., Holt, A., Xu, X. X., Duan, L., Henderson, K., Bernstein, L., Ellenhorn, J.

    • Surgical resection and multidisciplinary care for primary and metastatic pancreatic islet cell carcinomas.

      McKenzie, S., Lee, W., Artinyan, A., Mailey, B., Pigazzi, A., Ellenhorn, J., Kim, J.

    • Human papillomavirus infection as a prognostic factor in oropharyngeal squamous cell carcinomas treated in a prospective phase II clinical trial.

      Jo, S., Juhasz, A., Zhang, K., Ruel, C., Loera, S., Wilczynski, S. P., Yen, Y., Liu, X., Ellenhorn, J., Lim, D., Paz, B., Somlo, G., Vora, N., Shibata, S.

    • Adjuvant radiation therapy is associated with improved survival for gallbladder carcinoma with regional metastatic disease.

      Mojica, P., Smith, D., Ellenhorn, J.

    • Skin-sparing mastectomy: a survey based approach to defining standard of care.

      Shen, J., Ellenhorn, J., Qian, D., Kulber, D., Aronowitz, J.

    • Pilot series of robot-assisted laparoscopic subtotal gastrectomy with extended lymphadenectomy for gastric cancer.

      Anderson, C., Ellenhorn, J., Hellan, M., Pigazzi, A.

    • NCCN Practice Guidelines for Head and Neck Cancers.

      Pfister, D. G., Ang, K., Brockstein, B., Colevas, A. D., Ellenhorn, J., Goepfert, H., Hicks, W. L., Hong, W. K., Kies, M. S., Lydiatt, W., McCaffrey, T., Mittal, B. B., Ridge, J. A., Schuller, D. E., Shah, J. P., Spencer, S., Trotti, A., Urba, S., Weymuller, E. A., Wheeler, R. H., Wolf, G. T.

    • Robotic surgery for gastrointestinal malignancies.

      Anderson, C., Hellan, M., Kernstine, K., Ellenhorn, J., Lai, L., Trisal, V., Pigazzi, A.

    • Clinical and functional properties of novel VHL mutation (X214L) consistent with Type 2A phenotype and low risk of renal cell carcinoma.

      Sorrell, A. D., Lee, S., Stolle, C., Ellenhorn, J., Grix, A., Kaelin, W. G., Weitzel, J. N.

    • Immunopotentiation of anti-viral and anti-tumor immune responses using anti-T cell receptor antibodies and mitogens.

      Newell, K. A., Ellenhorn, J. D., Hirsch, R., Bluestone, J. A.

    • In vivo T-cell activation by staphylococcal enterotoxin B prevents outgrowth of a malignant tumor.

      Newell, K. A., Ellenhorn, J. D., Bruce, D. S., Bluestone, J. A.

    • Mechanism of tumor rejection in anti-CD3 monoclonal antibody-treated mice.

      Ellenhorn, J. D., Schreiber, H., Bluestone, J. A.

    • Activation of human T cells in vivo following treatment of transplant recipients with OKT3.

      Ellenhorn, J. D., Woodle, E. S., Ghobreal, I., Thistlethwaite, J. R., Bluestone, J. A.

    • Treatment with monoclonal anti-CD3 antibody protects against lethal Sendai virus infection by induction of natural killer cells.

      Kast, W. M., Bluestone, J. A., Heemskerk, M. H., Spaargaren, J., Voordouw, A. C., Ellenhorn, J. D., Melief, C. J.

    • Evaluation of routine radiation boost following breast conservation therapy in young patients.

      Lamont JP, Faynsod M, Smith D, Pezner R, Ellenhorn JDI

    • Paint only is equivalent to scrub and paint for the preoperative preparation of breast and axillary surgery sites.

      Ellenhorn JD, Chu DZ, Wagman LD, Smith DD, Schwarz RE, Paz IB

    • Chemotherapy response predicts survival in patients with advanced non-laryngeal squamous cell carcinoma of the head and neck undergoing organ preservation surgery.

      Cullinane CA, Vora N, Ellenhorn JD, Carter N, Shibata S, Wagman LD, Paz IB

    • Transanal excision for low rectal cancer curative in early stage disease with favorable histology.

      Blair, S., Ellenhorn, JDI

    • Specific recognition of human p53 overexpressing tumor cells by an HLA A2.1-restricted murine T cell receptor expressed in Jurkat T cells.

      Liu XP, Peralta EA, Diamond DL, Ellenhorn JDI